{"id":"W2917035693","doi":"10.1001/jamanetworkopen.2019.0035","title":"Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Spark Therapeutics; Genentech; Regeneron Pharmaceuticals; AstraZeneca; Laura and John Arnold Foundation; Kaiser Permanente; GlaxoSmithKline; Blue Shield of California Foundation; Sanofi; National Pharmaceutical Council; Mallinckrodt Pharmaceuticals; Alnylam Pharmaceuticals; California Health Care Foundation","keywords":"Medicine; Oncology; Lymphoma; Survival analysis; Internal medicine; Cost effectiveness; Quality-adjusted life year; Cohort","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009299371,0.0002541756,0.000876319,0.00005188526,0.00007168294,0.00008913251,0.0002222507,0.0001659724,0.0005670891],"category_scores_gemma":[0.00001998143,0.0001886018,0.0001132998,0.0002684005,0.00008556002,0.0001035089,0.00008121492,0.00005793138,0.000009448388],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003524616,"about_ca_system_score_gemma":0.0002150408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001401803,"about_ca_topic_score_gemma":0.00008395132,"domain_scores_codex":[0.9982951,0.0002384084,0.0002410086,0.0004462432,0.0003120212,0.0004672564],"domain_scores_gemma":[0.998179,0.0008134208,0.0001585096,0.0004750869,0.0002043651,0.0001696745],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04179999,0.002315554,0.7867994,0.0002544653,0.001297718,0.00004058759,0.0002860883,0.00006820643,0.02809306,0.00004160403,0.0002487989,0.1387545],"study_design_scores_gemma":[0.06696442,0.007581338,0.890977,0.0004662583,0.0001435581,0.00001373828,0.00003837215,0.0004911969,0.02958317,0.00002381964,0.003469755,0.0002473755],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860716,0.0004638788,0.0001288529,0.0002596858,0.0001118563,0.007487858,0.00003067257,0.00002454879,0.005421075],"genre_scores_gemma":[0.9831151,0.0006280864,0.0002097092,0.0001344273,0.0002263197,0.0004680267,0.0001720637,0.0000853351,0.01496092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1385071,"threshold_uncertainty_score":0.7690959,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04220927045853014,"score_gpt":0.3345751585168903,"score_spread":0.2923658880583602,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}